1. Home
  2. PEBK vs SABS Comparison

PEBK vs SABS Comparison

Compare PEBK & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peoples Bancorp of North Carolina Inc.

PEBK

Peoples Bancorp of North Carolina Inc.

HOLD

Current Price

$36.10

Market Cap

157.0M

Sector

Finance

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.73

Market Cap

181.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEBK
SABS
Founded
1912
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.0M
181.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PEBK
SABS
Price
$36.10
$3.73
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.50
AVG Volume (30 Days)
11.2K
299.4K
Earning Date
02-11-2026
11-13-2025
Dividend Yield
2.65%
N/A
EPS Growth
3.81
N/A
EPS
3.06
N/A
Revenue
$85,500,000.00
$114,698.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.83
N/A
Revenue Growth
6.88
N/A
52 Week Low
$23.74
$1.00
52 Week High
$38.46
$6.60

Technical Indicators

Market Signals
Indicator
PEBK
SABS
Relative Strength Index (RSI) 57.46 49.71
Support Level $36.15 $3.48
Resistance Level $38.40 $4.00
Average True Range (ATR) 0.79 0.19
MACD -0.32 -0.04
Stochastic Oscillator 10.61 42.96

Price Performance

Historical Comparison
PEBK
SABS

About PEBK Peoples Bancorp of North Carolina Inc.

Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: